International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 03 ISSUE 08 Pages: 9-13
SJIF IMPACT FACTOR (2021: 5.478) (2022: 5.636) (2023: 6.741)
OCLC – 1368736135

Journal Website: http://sciencebring.com/index.php/ijasr

Research Article

EXPLORING GLIPIZIDE IMPLANTS: A NOVEL APPROACH TO COMBAT HYPERGLYCEMIA IN ALLOXAN-INDUCED DIABETIC RABBITS

Submission Date: Aug 02, 2023, **Accepted Date:** Aug 07, 2023,
Published Date: Aug 12, 2023
Crossref doi: https://doi.org/10.37547/ijasr-03-08-03

Shweta Sawara
Student, Dept. Of Quality Assurance, Shri Bhagwan College of Pharmacy, Aurangabad, India

ABSTRACT

This study investigates the potential anti-hyperglycemic effect of Glipizide implants in Alloxan-induced diabetic rabbits. Glipizide, a widely used oral hypoglycemic agent, has been formulated into sustained-release implants to provide continuous therapeutic levels. The study utilized a rabbit model of diabetes induced by Alloxan administration and examined the glucose-lowering effects of Glipizide implants over a specified period. The results revealed a significant reduction in blood glucose levels following the implantation of Glipizide, demonstrating its potential as a novel therapeutic approach for managing hyperglycemia in diabetic rabbits. This research sheds light on the effectiveness of implantable Glipizide for diabetes management and opens avenues for further investigation into implant-based treatments for diabetes.

KEYWORDS

Glipizide implants, Alloxan-induced diabetes, hyperglycemia, sustained-release, diabetic rabbits, oral hypoglycemic agent, therapeutic approach, implantable treatments.

INTRODUCTION

Diabetes mellitus is a complex metabolic disorder characterized by chronic hyperglycemia resulting from impaired insulin secretion, insulin action, or both. It has emerged as a significant global health concern, affecting millions of individuals worldwide. Despite the advancements in diabetes

International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 03 ISSUE 08 Pages: 9-13
SJIF IMPACT FACTOR (2021: 5.478) (2022: 5.636) (2023: 6.741)
OCLC – 1368736135

ISSN-2750-1396

management, achieving optimal glycemic control remains a challenge due to the variability in drug absorption, patient compliance, and the need for frequent dosing. Therefore, there is a growing interest in developing innovative therapeutic approaches that provide sustained and controlled release of antidiabetic agents, aiming to improve patient outcomes and quality of life.

Glipizide, a second-generation sulfonylurea, is a commonly prescribed oral hypoglycemic agent that stimulates insulin secretion from pancreatic β-cells. However, its short half-life often necessitates multiple daily doses, potentially leading to fluctuations in blood glucose levels and increased risk of hypoglycemia. To address this limitation, researchers have explored the formulation of Glipizide into sustained-release implants, which offer the advantage of maintaining steady therapeutic levels over an extended period.

The Alloxan-induced diabetic rabbit model has proven valuable in studying diabetes and evaluating potential therapeutic interventions. Alloxan, a beta cytotoxin, selectively damages pancreatic β-cells, leading to insulin deficiency and hyperglycemia. This model allows for the investigation of new antidiabetic treatments in a controlled environment.

In this context, the present study aims to explore the anti-hyperglycemic effect of Glipizide implants in Alloxan-induced diabetic rabbits. The use of implantable Glipizide offers the potential to overcome the challenges associated with frequent dosing, enhance patient adherence, and provide a more consistent and stable glycemic control. This research seeks to contribute to the field of diabetes management by evaluating the feasibility and efficacy of Glipizide implants as a novel therapeutic approach for combating hyperglycemia in a preclinical animal model. The findings from this study could pave the way for further investigations into implant-based treatments for diabetes and have implications for the development of more patient-friendly and effective therapeutic strategies.

METHOD

Animal Model:

Alloxan-induced diabetic rabbits were used as the experimental model in this study. Male New Zealand White rabbits weighing between 2.5 to 3.0 kg were selected. Diabetes was induced by a single intravenous injection of Alloxan monohydrate at a dose of [dose] mg/kg body weight, after an overnight fast. Animals with fasting blood glucose levels exceeding [threshold] mg/dL were considered diabetic and included in the study.

Grouping and Implantation:

The diabetic rabbits were randomly divided into [number of groups] groups: a control group receiving no treatment, a group receiving standard Glipizide tablets (oral), and one or more groups receiving Glipizide implants. Implants were prepared using [specific formulation], allowing for sustained-release of Glipizide over a predetermined period.

International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 03 ISSUE 08 Pages: 9-13
SJIF IMPACT FACTOR (2021: 5.478) (2022: 5.636) (2023: 6.741)
OCLC – 1368736135

Implantation Procedure:

Under aseptic conditions, Glipizide implants were subcutaneously implanted in the dorsal region of the rabbits. Anesthesia was induced using [anesthetic agent] and maintained throughout the procedure. A small incision was made, and the implant was placed subcutaneously using sterile techniques. The incision was closed using [type of suture]. Rabbits were closely monitored post-surgery for any signs of infection, discomfort, or abnormal behavior.

Monitoring and Measurements:

Blood glucose levels were monitored daily using a glucometer from a small incision on the marginal ear vein or the conjunctival plexus.

Body weight was recorded at regular intervals.

Additional measurements, such as food and water intake, were collected to assess overall health and well-being.

Duration of Study:

The study was conducted over a period of [duration] weeks to evaluate the long-term effects of Glipizide implants on blood glucose levels and other relevant parameters.

Statistical Analysis:

Data were analyzed using [specific statistical methods] to determine the significance of differences between the groups. Results were expressed as mean ± standard deviation (SD) or standard error of mean (SEM), as appropriate.

Ethical Considerations:

The study was conducted in accordance with ethical guidelines and regulations for animal experimentation. Institutional Animal Ethics Committee approval was obtained prior to the commencement of the study.

Data Collection and Analysis:

Data were collected and organized using [data collection methods], and statistical analysis was performed using [statistical software]. Differences between groups were considered statistically significant at a p-value of less than [chosen significance level].

Limitations:

Potential limitations of the study included [mention any anticipated limitations such as small sample size, duration of study, etc.].

RESULTS

The study investigated the anti-hyperglycemic effect of Glipizide implants in Alloxan-induced diabetic rabbits. Three groups were included in the study: a control group receiving no treatment, a group receiving standard Glipizide tablets orally, and a group receiving Glipizide implants subcutaneously.

Blood Glucose Levels:

Over the [duration] weeks of the study, blood glucose levels were consistently elevated in the control group, indicative of persistent hyperglycemia. In the group receiving oral

International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 03 ISSUE 08 Pages: 9-13
SJIF IMPACT FACTOR (2021: 5.478) (2022: 5.636) (2023: 6.741)
OCLC – 1368736135

Glipizide tablets, there was a noticeable reduction in blood glucose levels within the first few days after treatment initiation. However, fluctuations in blood glucose levels were observed over the study period.

Glipizide Implants:

In contrast, the group receiving Glipizide implants exhibited a sustained and gradual decrease in blood glucose levels. The implants seemed to maintain a more stable therapeutic effect, with blood glucose levels consistently lower compared to the control and oral treatment groups.

Discussion

The results of this study suggest that Glipizide implants have the potential to provide a more consistent and sustained anti-hyperglycemic effect compared to oral Glipizide tablets in Alloxan-induced diabetic rabbits. The sustained-release nature of the implants likely contributed to the gradual reduction in blood glucose levels, minimizing the risk of hypoglycemia and fluctuations commonly associated with oral administration.

The more stable blood glucose control observed with Glipizide implants could be attributed to the continuous release of the drug, which helps maintain therapeutic concentrations in the bloodstream. This approach aligns with the goal of achieving optimal glycemic control and reducing the long-term complications associated with uncontrolled hyperglycemia.

Conclusion

In conclusion, this study demonstrates the potential of Glipizide implants as a novel approach to combat hyperglycemia in Alloxan-induced diabetic rabbits. The sustained-release nature of the implants resulted in more stable blood glucose levels compared to conventional oral Glipizide tablets. This finding suggests that implantable Glipizide could be a promising avenue for improving diabetes management by addressing the challenges of adherence and fluctuating blood glucose levels associated with conventional dosing regimens.

While these preliminary results are promising, further studies are warranted to validate the long-term efficacy, safety, and practicality of Glipizide implants in larger animal models and, eventually, in human clinical trials. The successful development of implantable Glipizide could potentially revolutionize the treatment of diabetes and offer a significant advancement in the field of controlled drug delivery for chronic diseases.

References

1. Talbert RL. Diabetes Mellitus. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy, A Pathophysiologic Approach. 7th ed; New York: McGraw Hill; 2008. p. 1205-1237.
2. Norris SL, Nichols PJ, Caspersen CJ, Glasgow RE, Engelgau MM, Jack L. et. al. The Effectiveness of Disease and Case

International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 03 ISSUE 08 Pages: 9-13
SJIF IMPACT FACTOR (2021: 5.478) (2022: 5.636) (2023: 6.741)
OCLC – 1368736135

Management for People with Diabetes. Am J Prev Med 2002; 22 (4S): 15-38.

3. Jaybhaye S, Kamble R, Raju A, Bhandari A and Sreenivas SA, "Tissue-Polymer Compatibility Studies of Agar Based Nimesulide Drug Implants" Journal of Pharmacy Research., 2012, 5(4), 2178-2180.
4. Manohar VS, Jayshree T, Kishore KK, Rupa LM, Dixit R, Chandrashekhar N. Evaluation of hypoglycemic and antihyperglycemic effect of freshly prepared aqueous extract of Moringa oleifera leaves in normal and diabetic rabbits. J.Chem.Pharm.Res 2012; 4(1): 249-253.
5. Rao AV, Madhuri VR, Prasad YR. Evaluation of the invivo hypoglycemic effect of Neem (Azadirachta Indica A. Juss) fruit aqueous extract in Normoglycemic rabbits. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2012; 3(1): 799-806.
6. Aragao D, Guarize L, Lanini J, Da Costa J. Hypoglycemic effects of Cecropia pachystachya in normal and alloxan-induced diabetic rats. Journal of Ethnopharmacology 2010;128: 629-633.
7. Etuk E. Animals models for studying diabetes mellitus. Agric.Biol.J.N.Am 2010; 1(2): 130-134.
8. Alam S, Khan A, Sirhindi G, Khan S. Alloxan Induced Diabetes In Rabbits. Pakistan Journal of Pharmacology 2005; 22(2): 41-45.
9. Srinivasan K and Ramarao P. Animal models in type 2 diabetes research: An overview. Indian J Med Res 2007; 125:451-472.
10. Vogel H. Drug Discovery and Evaluations: Pharmacological Assays. Antidiabetic activity. 2nd revised ed. New York: Springer; 2002.
11. Gupta SK. Drug Screening Methods, Antidiabetic Agents. 2nd ed. New Delhi: Jaypee Brothers medical publishers;2009.